Uric Acid Nephrolithiasis: A Systemic Metabolic Disorder
- PMID: 25045326
- PMCID: PMC4100778
- DOI: 10.1007/s12018-011-9106-6
Uric Acid Nephrolithiasis: A Systemic Metabolic Disorder
Abstract
Uric acid nephrolithiasis is characteristically a manifestation of a systemic metabolic disorder. It has a prevalence of about 10% among all stone formers, the third most common type of kidney stone in the industrialized world. Uric acid stones form primarily due to an unduly acid urine; less deciding factors are hyperuricosuria and a low urine volume. The vast majority of uric acid stone formers have the metabolic syndrome, and not infrequently, clinical gout is present as well. A universal finding is a low baseline urine pH plus insufficient production of urinary ammonium buffer. Persons with gastrointestinal disorders, in particular chronic diarrhea or ostomies, and patients with malignancies with a large tumor mass and high cell turnover comprise a less common but nevertheless important subset. Pure uric acid stones are radiolucent but well visualized on renal ultrasound. A 24 h urine collection for stone risk analysis provides essential insight into the pathophysiology of stone formation and may guide therapy. Management includes a liberal fluid intake and dietary modification. Potassium citrate to alkalinize the urine to a goal pH between 6 and 6.5 is essential, as undissociated uric acid deprotonates into its much more soluble urate form.
Keywords: Acid urine; Alkaline; Ammonium; Gout; Hyperuricosuria; Metabolic syndrome; Potassium citrate; Uric acid nephrolithiasis; Urine buffer; pH.
Figures
Similar articles
-
Nephrolithiasis.2020 Mar 9. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. 2020 Mar 9. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. PMID: 25905296 Free Books & Documents. Review.
-
Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group.Arch Ital Urol Androl. 2015 Jul 7;87(2):105-20. doi: 10.4081/aiua.2015.2.105. Arch Ital Urol Androl. 2015. PMID: 26150027 Review.
-
The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance.Kidney Int. 2004 Feb;65(2):386-92. doi: 10.1111/j.1523-1755.2004.00386.x. Kidney Int. 2004. PMID: 14717908
-
Renal ammonium excretion after an acute acid load: blunted response in uric acid stone formers but not in patients with type 2 diabetes.Am J Physiol Renal Physiol. 2013 Nov 15;305(10):F1498-503. doi: 10.1152/ajprenal.00374.2013. Epub 2013 Sep 11. Am J Physiol Renal Physiol. 2013. PMID: 24026180 Free PMC article.
-
Dissolution of radiolucent renal stones by oral alkalinization with potassium citrate/potassium bicarbonate.Arch Ital Urol Androl. 2009 Sep;81(3):188-91. Arch Ital Urol Androl. 2009. PMID: 19911683
Cited by
-
Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for recurrent nephrolithiasis among patients with pre-existing nephrolithiasis or gout: target trial emulation studies.BMJ. 2024 Oct 30;387:e080035. doi: 10.1136/bmj-2024-080035. BMJ. 2024. PMID: 39477370 Free PMC article.
-
Prevalence and risk factors for hyperuricemia and hyperuricosuria in patients with hematologic malignancies.Front Med (Lausanne). 2024 May 30;11:1343000. doi: 10.3389/fmed.2024.1343000. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38873194 Free PMC article.
-
Increased risk of chronic kidney disease in uric acid stone formers with high neutrophil-to-lymphocyte ratio.Sci Rep. 2023 Oct 17;13(1):17686. doi: 10.1038/s41598-023-45034-1. Sci Rep. 2023. PMID: 37848540 Free PMC article.
-
Efficacy of Theobromine and Its Metabolites in Reducing the Risk of Uric Acid Lithiasis.Int J Mol Sci. 2023 Jun 29;24(13):10879. doi: 10.3390/ijms241310879. Int J Mol Sci. 2023. PMID: 37446053 Free PMC article.
-
Dysuricemia-A New Concept Encompassing Hyperuricemia and Hypouricemia.Biomedicines. 2023 Apr 23;11(5):1255. doi: 10.3390/biomedicines11051255. Biomedicines. 2023. PMID: 37238926 Free PMC article. Review.
References
-
- Balinsky JB. Phylogenetic aspects of purine metabolism. S Afr Med J. 1972;46(29):993–7. - PubMed
-
- Campbell JW. Comparative biochemistry of nitrogen metabolism. In: Campbell JW, editor. The vertebrates. Vol. 2. New York: Academic Press; 1970.
-
- Moe OW. Uric acid nephrolithiasis: proton titration of an essential molecule? Curr Opin Nephrol Hypertens. 2006;15(4):366–73. - PubMed
-
- Shoemaker VH, et al. Uricotelism and low evaporative water loss in a South American frog. Science. 1972;175(25):1018–20. - PubMed
-
- Christen P, et al. Urate oxidase in primates. Folia Primatol (Basel) 1970;13(1):35–9. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources